Ascentage Pharma Group International ADR(AAPG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.26 | Insider Own | - | Shs Outstand | 52.2M | Perf Week | -6.37% |
| Market Cap | 1.35B | Forward P/E | - | EPS next Y | 7.25% | Insider Trans | - | Shs Float | - | Perf Month | -9.08% |
| Enterprise Value | 1.38B | PEG | - | EPS next Q | -0.36 | Inst Own | 0.02% | Short Float | - | Perf Quarter | -13.98% |
| Income | -0.21B | P/S | 14.69 | EPS this Y | 75.28% | Inst Trans | 4.27% | Short Ratio | 2.61 | Perf Half Y | -38.06% |
| Sales | 0.09B | P/B | 16.39 | EPS next 5Y | 48.61% | ROA | -46.64% | Short Interest | 0.02M | Perf YTD | -44.91% |
| Book/sh | 0.88 | P/C | 4.83 | EPS past 3/5Y | 0.8% -1.32% | ROE | -240.66% | 52W High | -58.1% ($34.50) | Perf Year | -55.82% |
| Cash/sh | 2.99 | P/FCF | - | Sales past 3/5Y | 36.88% 113.42% | ROIC | -121.48% | 52W Low | 0.01% ($14.45) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -12.46% | Gross Margin | 83.18% | Volatility(W/M) | 2.75% 3.23% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 15.02 | Sales Y/Y TTM | 69.8% | Oper. Margin | -220% | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.18 | EPS Q/Q | - | Profit Margin | -229.27% | RSI (14) | 42.13 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.22 | Sales Q/Q | - | SMA20 | -4.52% ($15.14) | Beta | 0.12 | Target Price | $43.56 |
| Payout | - | Debt/Eq | 3.76 | Earnings | 2026/8/18 | SMA50 | -8.88% ($15.87) | Rel Volume | 2.29 | Prev Close | $14.88 |
| Employees | 767 | LT Debt/Eq | 1.11 | EPS/Sales Surpr. | -490.95% -16.37% | SMA200 | -28.88% ($20.33) | Avg Volume(3M) | 0.01M | Price | $14.46 |
| IPO | 2025/1/27 | Option/Short | No/Yes | Trades | 164 | Volume | 15,926 | Change | -2.85% |
🧬 This is a China-based biopharmaceutical company that develops and commercializes cancer therapeutics. Using technology that targets cell death pathways, the company develops treatments for blood cancers and other indications. Its operating model combines commercialized products in China with a global clinical pipeline and pharmaceutical partnerships. It has established itself as a differentiated oncology biotech with a cell death-targeting approach.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded more than usual. That is 229% of its average volume.
AAPG has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +75.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,469. Peers typically go for $1,268.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
ECNS iShares MSCI China Small-Cap ETF <0.01% 
CXSE WisdomTree China ex-State-Owned Enterprises Fund <0.01% 
EEMS iShares MSCI Emerging Markets Small-Cap ETF <0.01% 
VSS Vanguard FTSE All-World Ex-US Small Capital Index Fund ETF <0.01% 
KAIT KraneShares Asia AI Technology ETF <0.01% It ranks #134 of 597 in the industry
Based on market cap of $1B.
AAPG#134 Ascentage Pharma Group International ADR $1B PER - 
TSHA#135 Taysha Gene Therapies Inc $1B PER - 
OMER#136 Omeros Corp $1B PER 12.8 
NKTR#137 Nektar Therapeutics $1B PER - 
DMRA#138 Damora Therapeutics Inc $1B PER - 
FAQ
What kind of company is AAPG?
AAPG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AAPG?
The market cap of AAPG is approximately $1.3B, ranking 2,356 within its sector.
What is the 52-week high and low for AAPG?
AAPG has recorded a 52-week high of $34.50 and a low of $14.45.
